Darwin is our deep machine learning platform. The foundation of Darwin consists of customizable training data sets that are designed based on biological mechanisms, data from functional genomics, and proteomics.
Focus is on real-time data mining that will enable Darwin to evolve its training sets moving forward. It is using an ensemble method with adversarial learning for high-quality data output.
novAIZen is committed not only to drug discovery for Central Nervous System Disorders but also to expand Darwin as a broad spectrum platform that is customizable to other fields of medicine.
Synapses That Are Not Built Right, Do Not Work Right.
Functional brain circuits are built through the specialized cell to cell contacts called Synapses. Synapses are formed at massive scale near birth and are later fine-tuned via experience-dependent elimination and maturation.
Darwin analyzes and interprets large sets of gene families and signaling cascades that are known to regulate the formation, elimination, and maturation of synapses, and reveals therapeutic nodes in the genetic networks.
Synapses Can Fine-Tune Circuits
... but Not in A Diseased Brain
Synaptic Plasticity is the ability of any synapse to change its strength in response to information flow. This is the underlying mechanism for our brain to process, store and retrieve information. This process takes place at a single synapse level as well as in a homeostatic fashion where group of synapses fine-tune their strength as a part of the ensemble.
Darwin runs single synapse simulations to understand the molecular basis of synaptic plasticity and reveals fixes for malfunctioning machinery at the in silico synapses.
Neurodegeneration: Race Against Time.
Brains suffering from neurodegeneration undergo a progressive loss of structure and function at cellular and circuit levels. Different neurodegenerative diseases may have different initiation points that can be cell type specific or gene specific but most share parallels at the sub cellular level.
Several pathways uncovered in studies related to neurodegeneration, ischemia, apoptosis and cell death are being investigated for potential drug candidates for neuroprotection.
